Seattle Genetics’ $600 Million Equity Offering

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC-registered offering by Seattle Genetics, Inc. of 13,269,230 shares of common stock, which includes 1,730,769 shares of common stock sold pursuant to the exercise of the underwriters’ over-allotment option.

Barclays and J.P. Morgan acted as underwriters on the offering

Seattle Genetics is a biotechnology company focused on the development and commercialization of targeted therapies for the treatment of cancer. The company, led by Clay B Siegall, Todd E Simpson and Vaughn B Himes, in 2017 recorded $482 Million Revenues.

The Davis Polk corporate team included partner Alan F. Denenberg (Picture), counsel Jason Bassetti and associates Xin (Anita) Guo, Benson Richards and Lucas Tejwani. Partner Rachel D. Kleinberg and associate Caroline E. Dayton provided tax advice. Counsel Michelle Ontiveros Gross and associate Jason J. Bang provided intellectual property and technology advice.

Involved fees earner: Alan Denenberg – Davis Polk & Wardwell; Jason Bassetti – Davis Polk & Wardwell; Xin Guo – Davis Polk & Wardwell; Benson Richards – Davis Polk & Wardwell; Lucas Tejwani – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; Caroline Dayton – Davis Polk & Wardwell; Michelle Ontiveros Gross – Davis Polk & Wardwell; Jason Bang – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Barclays Bank; JP Morgan;


Author: Ambrogio Visconti